4 recruiting, 2 active not recruiting, 1 unknown. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 4, Active not recruiting 2, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow DLBCL - Diffuse Large B Cell Lymphoma: new trials by email Literature Review of DLBCL - Diffuse Large B Cell Lymphoma trials Research Report on DLBCL - Diffuse Large B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-11-06 |
| This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma LTZ-301 - Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | LTZ Therapeutics, Inc. | 42 | 2026-01-29 | 2026-07-24 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta Cyclophosphamide, TLI - DLBCL - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | University Health Network, Toronto | 40 | 2023-07-14 | 2025-12-08 |
| Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Bridging radiation therapy, Liso-cel, Post-infusion radiation - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | University of Nebraska | 33 | 2023-03-21 | 2026-10-08 |
| Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies KUR-502 - NHL, Relapsed, Adult, B-cell Lymphoma | Phase 1 | Unknown | Athenex, Inc. | 36 | 2022-10-01 | 2023-05-18 |
Dendritic Cell Sarcoma, Interdigitating (7) · Lymphoma, Follicular (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Waldenstrom Macroglobulinemia (2) · Leukemia, B-Cell (1) · Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Pyloric Stenosis, Hypertrophic (1) · Recurrence (1)
Hemic and Lymphatic Diseases (7) · Histiocytic Disorders, Malignant (7) · Histiocytosis (7) · Lymphatic Diseases (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Lymphoma (5) · Hematologic Diseases (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2)
Automobiles (1) · Cyclophosphamide (1) · Receptors, Chimeric Antigen (1)
Athenex, Inc. (1) · LTZ Therapeutics, Inc. (1) · ModeX Therapeutics, An OPKO Health Company (1) · Poseida Therapeutics, Inc. (1) · University Health Network, Toronto (1) · University of Nebraska (1) · Verismo Therapeutics (1)
United States (5) · Australia (1) · Canada (1) · Israel (1) · Spain (1)
Carlos Ramos, MD (1) · Christopher R D'Angelo, MD (1) · Laura A Johnson, PhD (1) · Simon Heidegger, MD (1)